Members of the Blue Matter European Biotech Leader Roundtable met on 22 September 2022 in Zug, Switzerland to discuss US/EU corporate governance for biopharma companies launching into European markets. The meeting’s objectives were to:
- Define US/EU governance and align on its purpose
- Pinpoint key governance issues, as well as their root causes and implications
- Identify a set of actionable solutions and best practices to address key governance
issues
This document provides a high-level summary of the event. A more detailed white paper will be forthcoming.
